A Phase 2 interventional study of Dupilumab and Placebo in Atopic Dermatitis (AD), sponsored by Regeneron Pharmaceuticals. Completed at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-18.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.
Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 29th largest by enrollment, is one of 3 that started in 2013, is one of 7 in phase 2, and was the 6th registered.
1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.
Browse Dermatitis, Atopic studies →4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 6–17
University of California, San Francisco · Sites in United States
Ages 18+
University of Michigan · Sites in United States
Ages 18+
Sanofi
Ages 18+
By country, each count listing its studies:
dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, dupilumab is the treatment under test here. Read study by study →
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 12 · Phase 4 24
First in 2011; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 54 is below the median of 82 across 1,249 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 75 across the 50 interventional studies. Of the 38 that completed or were terminated, 26 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 50 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals: 1 open now, 2 under way, none of them phase 3. Of 27 finished, 18 (67%) have results posted.
Among the 30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals, this one is the 20th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2013, is one of 8 in phase 2, and was the 7th registered.
Regeneron Pharmaceuticals’s Dermatitis, Atopic studies by the year they started, since 2011.
4 of the studies testing dupilumab in Dermatitis, Atopic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07905547SanofiA Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis | 2027-02-07 |
| NCT05983068SanofiA Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis | 2027-04-29 |
| NCT05042258Northwestern UniversityUsing Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis | 2027-06 |
| NCT05268107University of MichiganEthnic Differences in Mechanisms of Action of Dupilumab | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 50 studies testing dupilumab in Dermatitis, Atopic, from their registry updates:
Among Regeneron Pharmaceuticals’s 30 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study was to assess the efficacy of Dupilumab, compared to placebo, in adult patients with moderate-to-severe atopic dermatitis (AD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The following treatments within 4 weeks before the baseline visit, or any condition that, in the opinion of the investigator, will likely require such treatment(s) during the first 4 weeks of study treatment:
Note: The information listed above is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial therefore not all inclusion/exclusion criteria are listed.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection once weekly (qw) from Week 1 to Week 15.
Drug: Placebo · Other: Background treatment
Two subcutaneous injections of Dupilumab 200 milligram (mg) (for a total of 400 mg) as a loading dose on Day 1, followed by a single 200 mg injection qw from Week 1 to Week 15.
Drug: Dupilumab · Other: Background treatment
Also known as: REGN668, SAR231893, Dupixent
Matching placebo
Participants were required to apply stable doses of a topical emollient (moisturizer) twice daily for at least 7 days before the baseline visit and at least 7 days after the baseline visit (day -7 to day 8).
Also known as: Topical emollient
Percent Change From Baseline in the Eczema Area Severity Index Score (EASI) to Week 16
The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema (E), infiltration (I), excoriation (Ex) and lichenification (L) on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Values after first rescue medication use were set to missing and missing values imputed by last observation carried forward (LOCF).
Time frame: Baseline to Week 16
Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" at Week 16
IGA was an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response was an IGA score of 0 (clear) or 1 (almost clear). Values after first rescue medication were set to missing and participants with missing IGA score at Week 16 were considered as non-responders.
Time frame: Week 16
Percentage of Participants Who Achieved IGA Score Reduction From Baseline of ≥2 Points at Week 16
IGA was an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Participants with reduction in IGA score from baseline of ≥2 points at Week 16 were reported. Values after first rescue medication were set to missing and participants with missing IGA score at Week 16 were treated as non-responders.
Time frame: Baseline to Week 16
Absolute Change From Baseline in Pruritus Numeric Rating Scale (NRS) at Week 16
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Values after first rescue treatment were set to missing and missing values were imputed by LOCF.
Time frame: Baseline to Week 16
Percent Change From Baseline in Pruritus Numeric Rating Scale (NRS) at Week 16
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Values after first rescue treatment were set to missing and missing values were imputed by LOCF.
Time frame: Baseline to Week 16
Absolute Change From Baseline in EASI Score to Week 16
The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Values after first rescue medication use were set to missing and missing values were imputed by LOCF.
Time frame: Baseline to Week 16
Absolute Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score to Week 16
SCORAD was a clinical tool for assessing the severity of atopic dermatitis developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) were assessed and scored. Total score ranged from 0 (absent disease) to 103 (severe disease). Values after first rescue medication use were set to missing and missing values were imputed by LOCF.
Time frame: Baseline to Week 16
Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score to Week 16
SCORAD is a clinical tool for assessing the severity of atopic dermatitis developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). Values after first rescue medication use were set to missing and missing values were imputed by LOCF.
Time frame: Baseline to Week 16
Percentage of Participants Who Achieved 50%, 75% and 90% Reduction From Baseline in EASI Score ( EASI-50, EASI-75, and EASI-90 Respectively) at Week 16
EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranged from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-50, EASI-75 and EASI-90 responders were the participants who achieved ≥50%, ≥75% and ≥90% respectively, overall improvement in EASI score from baseline to Week 16. Values after first rescue treatment were set to missing and participants with missing EASI score at Week 16 were counted as non-responders.
Time frame: Baseline to Week 16
Percentage of Participants Who Achieved 50%, 75% and 90% Reduction From Baseline in SCORAD Score (SCORAD-50, SCORAD-75 and SCORAD-90 Respectively) at Week 16
SCORAD was a clinical tool for assessing the severity of atopic dermatitis developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) were assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). SCORAD-50, SCORAD-75 and SCORAD-90 responders were the participants who achieved ≥50%, ≥75% and ≥90% respectively, overall improvement in SCORAD score from baseline to Week 16. Values after first rescue treatment were set to missing and participants with missing SCORAD score at Week 16 were counted as non-responders.
Time frame: Baseline to Week 16
Absolute Change From Baseline in Participant's Oriented Eczema Measure (POEM) Score to Week 16
POEM was a 7-item questionnaire that assessed disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]). Values after first rescue medication use were set to missing and missing values were imputed by LOCF.
Time frame: Baseline to Week 16
Percent Change From Baseline in Participant's Oriented Eczema Measure (POEM) Score to Week 16
POEM was a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]). Values after first rescue medication use were set to missing and missing values were imputed by LOCF.
Time frame: Baseline to Week 16
Change From Baseline in Global Individual Signs Score (GISS) Components (Erythema, Infiltration/Papulation, Excoriations, and Lichenification) to Week 16
Individual components of the AD lesions (erythema, infiltration/papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0 = none, 1 = mild, 2 = moderate and 3 = severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease).Values after first rescue medication use were set to missing and missing values were imputed by LOCF.
Time frame: Baseline to Week 16
Changes From Baseline in GISS Cumulative Score to Week 16
Individual components of the AD lesions (erythema, infiltration/papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0 = none, 1 = mild, 2 = moderate and 3 = severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease).Values after first rescue medication use were set to missing and missing values were imputed by LOCF.
Time frame: Baseline to Week 16
The study was conducted at 5 sites in USA and Canada between 05 December 2013 and 30 January 2015. A total of 66 participants were screened in the study.
| Milestone | Placebo qw | Dupilumab 200 mg qw |
|---|---|---|
| Started | 27 | 27 |
| Completed | 25 | 26 |
| Not completed | 2 | 1 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Adverse event | 0 | 1 |
The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema (E), infiltration (I), excoriation (Ex) and lichenification (L) on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Values after first rescue medication use were set to missing and missing values imputed by last observation carried forward (LOCF).
| percent change | Placebo qw | Dupilumab 200 mg qw |
|---|---|---|
| Percent Change From Baseline in the Eczema Area Severity Index Score (EASI) to Week 16 | -5.8 ± 8.16 | -75.2 ± 8.15 |
IGA was an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response was an IGA score of 0 (clear) or 1 (almost clear). Values after first rescue medication were set to missing and participants with missing IGA score at Week 16 were considered as non-responders.
| percentage of participants | Placebo qw | Dupilumab 200 mg qw |
|---|---|---|
| Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" at Week 16 | 0 | 37.0 |
IGA was an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Participants with reduction in IGA score from baseline of ≥2 points at Week 16 were reported. Values after first rescue medication were set to missing and participants with missing IGA score at Week 16 were treated as non-responders.
| percentage of participants | Placebo qw | Dupilumab 200 mg qw |
|---|---|---|
| Percentage of Participants Who Achieved IGA Score Reduction From Baseline of ≥2 Points at Week 16 | 3.7 | 51.9 |
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Values after first rescue treatment were set to missing and missing values were imputed by LOCF.
| units on a scale | Placebo qw | Dupilumab 200 mg qw |
|---|---|---|
| Absolute Change From Baseline in Pruritus Numeric Rating Scale (NRS) at Week 16 | -0.98 ± 0.398 | -3.64 ± 0.405 |
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Values after first rescue treatment were set to missing and missing values were imputed by LOCF.
| percent change | Placebo qw | Dupilumab 200 mg qw |
|---|---|---|
| Percent Change From Baseline in Pruritus Numeric Rating Scale (NRS) at Week 16 | -8.36 ± 8.098 | -56.44 ± 8.248 |
The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Values after first rescue medication use were set to missing and missing values were imputed by LOCF.
| units on a scale | Placebo qw | Dupilumab 200 mg qw |
|---|---|---|
| Absolute Change From Baseline in EASI Score to Week 16 | -3.7 ± 2.65 | -25.2 ± 2.65 |
SCORAD was a clinical tool for assessing the severity of atopic dermatitis developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) were assessed and scored. Total score ranged from 0 (absent disease) to 103 (severe disease). Values after first rescue medication use were set to missing and missing values were imputed by LOCF.
| units on a scale | Placebo qw | Dupilumab 200 mg qw |
|---|---|---|
| Absolute Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score to Week 16 | -5.1 ± 3.60 | -36.4 ± 3.60 |
SCORAD is a clinical tool for assessing the severity of atopic dermatitis developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). Values after first rescue medication use were set to missing and missing values were imputed by LOCF.
| percent change | Placebo qw | Dupilumab 200 mg qw |
|---|---|---|
| Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score to Week 16 | -8.2 ± 5.41 | -54.8 ± 5.40 |
EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranged from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-50, EASI-75 and EASI-90 responders were the participants who achieved ≥50%, ≥75% and ≥90% respectively, overall improvement in EASI score from baseline to Week 16. Values after first rescue treatment were set to missing and participants with missing EASI score at Week 16 were counted as non-responders.
| percentage of participants | Placebo qw | Dupilumab 200 mg qw |
|---|---|---|
| Participants with EASI-50 | 22.2 | 77.8 |
| Participants with EASI-75 | 14.8 | 66.7 |
| Participants with EASI-90 | 0 | 33.3 |
SCORAD was a clinical tool for assessing the severity of atopic dermatitis developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) were assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). SCORAD-50, SCORAD-75 and SCORAD-90 responders were the participants who achieved ≥50%, ≥75% and ≥90% respectively, overall improvement in SCORAD score from baseline to Week 16. Values after first rescue treatment were set to missing and participants with missing SCORAD score at Week 16 were counted as non-responders.
| percentage of participants | Placebo qw | Dupilumab 200 mg qw |
|---|---|---|
| Participants with SCORAD-50 | 7.4 | 55.6 |
| Participants with SCORAD-75 | 0 | 11.1 |
| Participants with SCORAD-90 | 0 | 7.4 |
POEM was a 7-item questionnaire that assessed disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]). Values after first rescue medication use were set to missing and missing values were imputed by LOCF.
| units on a scale | Placebo qw | Dupilumab 200 mg qw |
|---|---|---|
| Absolute Change From Baseline in Participant's Oriented Eczema Measure (POEM) Score to Week 16 | -2.6 ± 1.34 | -13.1 ± 1.37 |
POEM was a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]). Values after first rescue medication use were set to missing and missing values were imputed by LOCF.
| percent change | Placebo qw | Dupilumab 200 mg qw |
|---|---|---|
| Percent Change From Baseline in Participant's Oriented Eczema Measure (POEM) Score to Week 16 | -12.1 ± 6.18 | -58.3 ± 6.31 |
Individual components of the AD lesions (erythema, infiltration/papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0 = none, 1 = mild, 2 = moderate and 3 = severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease).Values after first rescue medication use were set to missing and missing values were imputed by LOCF.
| units on a scale | Placebo qw | Dupilumab 200 mg qw |
|---|---|---|
| Change in Erythema GISS | 0.0 ± 0.14 | -0.7 ± 0.14 |
| Change in Infiltration/Papulation GISS | -0.1 ± 0.13 | -1.0 ± 0.13 |
| Change in Excoriation GISS | -0.3 ± 0.14 | -1.3 ± 0.14 |
| Change in Lichenification GISS | -0.1 ± 0.14 | -1.2 ± 0.14 |
Individual components of the AD lesions (erythema, infiltration/papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0 = none, 1 = mild, 2 = moderate and 3 = severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease).Values after first rescue medication use were set to missing and missing values were imputed by LOCF.
| units on a scale | Placebo qw | Dupilumab 200 mg qw |
|---|---|---|
| Changes From Baseline in GISS Cumulative Score to Week 16 | -0.5 ± 0.46 | -4.2 ± 0.46 |
Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to the final visit (Week 32) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo qw | 0/27 (0%) | 3/27 (11.1%) | 17/27 (63%) |
| Dupilumab 200 mg qw | 0/27 (0%) | 0/27 (0%) | 20/27 (74.1%) |
| Event | Placebo qw | Dupilumab 200 mg qw |
|---|---|---|
| Coronary artery stenosisCardiac disorders | 1/27 | 0/27 |
| CholecystitisHepatobiliary disorders | 1/27 | 0/27 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 1/27 | 0/27 |
| Event | Placebo qw | Dupilumab 200 mg qw |
|---|---|---|
| NasopharyngitisInfections and infestations | 5/27 | 3/27 |
| Upper respiratory tract infectionInfections and infestations | 4/27 | 4/27 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 4/27 | 4/27 |
| Viral upper respiratory tract infectionInfections and infestations | 2/27 | 3/27 |
| Conjunctivitis allergicEye disorders | 0/27 | 2/27 |
| FatigueGeneral disorders | 1/27 | 2/27 |
| Injection site erythemaGeneral disorders | 1/27 | 2/27 |
| Injection site reactionGeneral disorders | 0/27 | 2/27 |
| FolliculitisInfections and infestations | 0/27 | 2/27 |
| GastroenteritisInfections and infestations | 0/27 | 2/27 |
| Age, Continuous(years) | Placebo qw | Dupilumab 200 mg qw | Total |
|---|---|---|---|
| Mean | 44.1 ± 15.73 | 38.5 ± 13.55 | 41.3 ± 14.81 |
| Sex: Female, Male(Participants) | Placebo qw | Dupilumab 200 mg qw | Total |
|---|---|---|---|
| Female | 13 | 11 | 24 |
| Male | 14 | 16 | 30 |
| Ethnicity (NIH/OMB)(Participants) | Placebo qw | Dupilumab 200 mg qw | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 |
| Not Hispanic or Latino | 25 | 26 | 51 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Placebo qw | Dupilumab 200 mg qw | Total |
|---|---|---|---|
| White | 20 | 19 | 39 |
| Black or African American | 3 | 3 | 6 |
| Asian | 3 | 5 | 8 |
| Other | 1 | 0 | 1 |
| Eczema Area and Severity Index (EASI) Score(units on a scale) | Placebo qw | Dupilumab 200 mg qw | Total |
|---|---|---|---|
| Mean | 34.2 ± 14.59 | 33.4 ± 15.41 | 33.8 ± 14.87 |
| Investigator Global Assessment (IGA) Score(units on a scale) | Placebo qw | Dupilumab 200 mg qw | Total |
|---|---|---|---|
| Mean | 3.5 ± 0.51 | 3.5 ± 0.51 | 3.5 ± 0.50 |
| Weekly Peak Pruritus Numeric Rating Scale (NRS)(units on a scale) | Placebo qw | Dupilumab 200 mg qw | Total |
|---|---|---|---|
| Mean | 7.4 ± 2.04 | 7.1 ± 2.42 | 7.3 ± 2.22 |
| Global Individual Signs Score (GISS) Total Score(units on a scale) | Placebo qw | Dupilumab 200 mg qw | Total |
|---|---|---|---|
| Mean | 8.9 ± 1.69 | 8.4 ± 1.82 | 8.6 ± 1.76 |
5 further baseline measures are reported on the registry.
Ran from Dec 2013 to primary completion in Dec 2014, 12 months.
Results were first posted in Mar 2020, 5 years 2 months after primary completion. A results delay was requested in Apr 2015.
Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 12 months is close to that.
Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab